Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives
- 51 Downloads
In this study, quality of life and psychiatric comorbid disorders were investigated in patients with cervical dystonia and their spouses and we also investigated the effect of botulinum toxin (BTX) treatment on these parameters.
Material and method
Thirty patients with cervical dystonia (CD) on BTX treatment and their spouses (n = 30) were included. Beck Depression Scale (BDS), State-Trait Anxiety Inventory I and II (STAI-I, STAI-II), Hospital Anxiety Scale (HAS), Hospital Depression Scale (HDS) for psychiatric comorbid disease assessment, Toronto Western Spasmodic Torticollis Scale (TWSTRS) for disease activity assessment, and Craniocervical Dystonia Questionnaire (CDQ-24), Cervical Dystonia Impact Profile (CDIP-58), and Short Form 36 (SF-36) questionnaires for quality of life assessment were used. BDS, STAI-I and STAI-II, HAS, HDS, and SF-36 scales were also obtained from the spouses. The same tests were applied both before and 8 weeks after the BTX treatment.
In our study, an increase in psychiatric comorbid disorders such as depression and anxiety was observed and the quality of life was adversely affected in all areas in patients. In the spouses of the patients, the rates of psychiatric comorbid disorders such as depression and anxiety were found to be increased when compared to healthy subjects while vitality, mental health, and general health perception were found to be negatively affected.
Patients showed improvements in anxiety level, disease activity, and overall quality of life scales after BTX treatment.
KeywordsCervical dystonia Botulinum toxin therapy Quality of life Depression Anxiety
This research did not receive any grants or funding from any funding agencies. The authors have no funding to report.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Zurowski M, McDonald WM, Fox S, Marsh L (2013) Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord 28. https://doi.org/10.1002/mds.25501
- 8.Akın YA, Akbostanci C, Mercan N, Aksun Z, Sorgun M (2012) Retrospective evaluation of 118 cervical dystonic cases treated with botulinum toxin Turk. J Neurol 18(3):104–107Google Scholar
- 11.Slawek J, Friedman A, Potulska A et al (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type a injections. Functl Neurol 22:95–100Google Scholar
- 13.Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W (2002) The Austrian botulinum toxin and dystonia study group. The impact of blepharospasm and cervical dystonia on health related quality of life and depression. J Neurol 249:842–846CrossRefGoogle Scholar
- 14.Fabbri M, Superbo M, Defazio G, Scaglione CLM, Antelmi E, Basini G, Nassetti S, Pizza F, Plasmati R, Liguori R (2014) Quality of life in patients with craniocervical dystonia: Italian validation of the “cervical dystonia impact profile(CDIP-58)” and the “Craniocervical dystonia questionnaire (CDQ-24) ”. Neurol Sci 35:1053–1058CrossRefGoogle Scholar
- 17.Kocaman G, Baslo MH, Hanağası H, Parman Y. İdyopatik servikal distonili hastalarda botulinum toksini uygulanmasından önce ve sonra kas aktivasyon paterninde görülen değişimlerin incelenmesi Nöropsikiyatri Arflivi 2009; 46: 39–43Google Scholar
- 19.Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J (2013) An open label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin a (Dysport). BMJ Open 3:e0011853. https://doi.org/10.1136/bmjopen-2012-001853 CrossRefGoogle Scholar